 SOUTH SAN FRANCISCO, Calif., Nov. 04, 2020 GLOBE NEWSWIRE -- Harpoon Therapeutics, Inc. Nasdaq: HARP, a clinical-stage immunotherapy company developing a novel class of T cell engagers, today reported financial results for the third quarter ended September 30, 2020 and provided a corporate update. 